Email : info@nexusalliancebiopharma.com
Contact : (321) 445-1969

Role of Vascular Endothelial Growth Factor Receptor Inhibitors in Refractory Cervical Cancer.

Abstract

This review article focuses on the past and future aspects of vascular endothelial growth factor inhibitors in Cervical Cancer.Vascular endothelial growth factor (VEGF)-mediated angiogenesis is considered to play a vital function in the tumor development and metastasis. Therefore, VEGF-inhibitors are being actively considered as prospective anticancer treatment. The most widely studied tyrosine kinase inhibitors that target VEGF or anti- VEGF monoclonal antibodies and receptors, promise significant results in clinical trials.

Key words: Vascular Endothelial Growth Factor; Tyrosine Kinase Inhibitor; Angiogenesis; Human Papilloma Virus; Anti-Angiogenesis Factor.

Download Pdf